Navigation Links
Studies Confirm Balloon Sinuplasty(TM) Helps Chronic Sinusitis Patients
Date:4/13/2008

Research Verifies Technology Is Safe, Patient-Friendly, Economical

MENLO PARK, Calif., April 14 /PRNewswire/ -- Two independent studies published this week in American Journal of Rhinology and Annals of Otology, Rhinology, & Laryngology confirm Balloon Sinuplasty(TM) technology safely opens narrow sinuses, is economical and highly satisfactory to chronic sinusitis patients. The peer-reviewed studies analyzed outcomes of more than 1,100 individuals treated with this minimally-invasive balloon technology from Acclarent, a leading developer of innovative medical technologies for ear, nose and throat surgeons.

Chronic sinusitis is an inflammation of the nasal sinuses afflicting an estimated 37 million Americans annually. Symptoms include facial pain or pressure, nasal discharge, difficulty breathing through the nose, and fatigue. Although antibiotics and topical steroids can help many people, approximately 500,000 U.S. patients undergo surgery each year to alleviate the symptoms of chronic sinusitis.

Balloon Sinuplasty(TM) technology is similar in concept to catheters used in the heart for balloon angioplasty. The specially designed devices are threaded into the sinus passageways and gently inflated, widening the passages to promote drainage and resolution of chronic sinusitis symptoms. The technology can be used alone or with standard surgical instrumentation.

Recovery times vary but patients typically return to normal activities within 24 hours of treatment. Since 2005, more than 2,500 sinus surgeons have been trained on this technology and treated more than 25,000 patients.

Studies Confirm Balloon Sinuplasty(TM) Benefits

Patients who underwent sinus surgery using Balloon Sinuplasty(TM) technology were more satisfied, felt better post-operatively and experienced less pain, according to data published in the current issue of American Journal of Rhinology. The 70 patient study also showed the total cost of these procedures was similar or lower for patients when compared with traditional surgical instrumentation.

"Our aim is to provide long lasting relief for our chronic sinusitis patients in a way that is more satisfying and less painful to recover from than the traditional surgical technique. Now we have a proven solution that allows us to provide this level of care with out additional cost in selected patients. This technique can be performed under local anesthesia and minimizes risk to the patients," said lead author and surgeon Michael Friedman, M.D., of The Advanced Center for Specialty Care in Chicago.

Separate data in the April 2008 issue of Annals of Otology, Rhinology, & Laryngology also concluded Balloon Sinuplasty(TM) instrumentation is safe and effective. More than 95 percent of the study's 1,036 patients enjoyed sinus symptom improvement over an average follow-up of 40 weeks and no adverse events were attributable to Balloon Sinuplasty(TM).

On behalf of the 34 surgeons who took part in the Annals study, Dr. Howard Levine, director of the Cleveland Nasal, Sinus and Sleep Center said, "The results from this study reinforce the outstanding safety record of Balloon Sinuplasty(TM) technology, and underscore its effectiveness in alleviating chronic sinusitis symptoms. Results were universally excellent across a large population of patients and dozens of different practices."

Bill Facteau, President and CEO of Acclarent, Inc., said, "These data further confirm the safety, efficacy, and high patient satisfaction that have previously been published in other studies on Balloon Sinuplasty(TM). The multiple investigators of these papers have also demonstrated the cost effectiveness and reported on the economic advantages to the healthcare system when using this established tool in sinus surgery."

About Acclarent

Acclarent, Inc. is a privately held medical device company in Menlo Park, CA that was established in June of 2004. Its singular focus is improving patient care in all areas of otolaryngology by developing and producing medical devices solely for Ear, Nose and Throat (ENT) specialists and their patients. Acclarent is demonstrating this by investing in innovative technologies, clinical studies, and physician training. The company received FDA clearance to market Balloon Sinuplasty(TM) technology in early 2005. For more information, visit http://www.acclarent.com.


'/>"/>
SOURCE Acclarent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Gene Studies of Male-Female Differences Often Flawed
2. Two studies published in the Lancet
3. Study of Studies Finds No Risk to Children From Phthalates in Toys
4. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
5. Studies Prove Exercise Can Heal the Body Mind and Soul
6. Studies Shed New Light on Breast Cancer, Treatment
7. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
Breaking Medicine Technology: